Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PPAR-gamma-agonists' renal effects.

H Izzedine1, V Launay-Vacher, I Buhaescu

  • 1Department of Nephrology, Pitie Salpetriere Hospital, Paris, France. hassan.izzedine@psl.ap-hop-paris.fr

Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology
|October 26, 2005
PubMed
Summary

PPAR-gamma ligands, like thiazolidinediones, improve insulin sensitivity and offer kidney protection in diabetes. These drugs may prevent diabetic nephropathy and glomerulosclerosis through direct renal effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice.

Medecine et maladies infectieuses·2019
Same author

Anticoagulants in frail patients. Seven situations at risk.

Journal de medecine vasculaire·2018
Same author

Renal function and venous thromboembolic diseases.

Journal des maladies vasculaires·2016
Same author

Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

The eye: a window on kidney diseases.

Clinical kidney journal·2015
Same author

Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Insulin resistance in diabetes mellitus is a growing concern.
  • PPAR-gamma ligands, including thiazolidinediones, are emerging treatments for diabetes.
  • Evidence suggests these ligands may offer renal protective benefits beyond glucose control.

Purpose of the Study:

  • To investigate the antiproteinuric and renal protective effects of PPAR-gamma ligands.
  • To explore the mechanisms underlying these renal benefits in diabetic models and patients.
  • To assess the potential of PPAR-gamma agonists as a novel strategy against diabetic nephropathy and sclerosis.

Main Methods:

  • Review of accumulating evidence from rodent models and human studies.
  • Analysis of studies on thiazolidinediones and other PPAR-gamma agonists.

Related Experiment Videos

  • Examination of effects on insulin sensitivity, proteinuria, blood pressure, and renal tissue markers.

    • Main Results:

    • PPAR-gamma ligands improve insulin sensitivity and exhibit antiproteinuric effects.
    • Troglitazone reduced extracellular matrix proteins and TGF-beta in diabetic rat glomeruli.
    • These ligands demonstrate antihypertensive effects and ameliorate glomerulosclerosis progression, independent of glucose-lowering effects.

    Conclusions:

    • PPAR-gamma ligands possess direct, beneficial renal effects in diabetes.
    • These agents may offer a novel intervention strategy to prevent vascular and glomerular sclerosis in diabetic nephropathy.
    • Further research into PPAR-gamma agonists could lead to new treatments for kidney complications in diabetes.